Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer

Phase 2

Terminated

Conditions: Anaplastic Thyroid Cancer

Interventions: Drug: paclitaxel
Drug: CA4P
Drug: carboplatin

First Posted Date: 2007-07-26

Last Posted Date: 2014-06-09

Lead Sponsor: Mateon Therapeutics

Target Recruit Count: 80

Registration Number: NCT00507429

Locations: 🇮🇳
Kidwai Memorial Hospital, Bangalore, Karnataka, India
🇮🇳
Christian Medial College, Vellore, Tamil Nadu, India
🇮🇹
INT Napoli Fondazione Pascale, Napoli, Italy

and more 38 locations

Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy

Phase 2

Terminated

Conditions: Uterine Neoplasms

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Paclitaxel

First Posted Date: 2007-07-23

Last Posted Date: 2011-09-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT00505492

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Washington School of Medicine, Seattle, Washington, United States

Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Topotecan
Drug: Ifosfamide
Drug: Carboplatin

First Posted Date: 2007-07-18

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00502892

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus

Phase 2

Completed

Conditions: Mixed Tumor, Mullerian

Interventions: Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2007-07-17

Last Posted Date: 2016-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00502203

Locations: 🇺🇸
Lyndon Baines Johnson Hospital, Houston, Texas, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Loma Linda Cancer Institute, Loma Linda, California, United States

and more 1 locations

Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions: Drug: Carboplatin
Drug: GM-CSF (Sargramostim)
Drug: Interferon Gamma

First Posted Date: 2007-07-16

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 59

Registration Number: NCT00501644

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Treatment of Tumors of the Choroid Plexus Epithelium

Phase 3

Terminated

Conditions: Choroid Plexus Tumors

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Vincristine
Radiation: Radiation Therapy

First Posted Date: 2007-07-13

Last Posted Date: 2020-02-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00500890

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

Phase 3

Completed

Conditions: Neuroblastoma

Interventions: Drug: carboplatin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: topotecan hydrochloride
Procedure: Surgery
Drug: Isotretinoin
Drug: Filgrastim

First Posted Date: 2007-07-11

Last Posted Date: 2021-07-06

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 464

Registration Number: NCT00499616

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

and more 186 locations

Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Docetaxel
Drug: Gemcitabine
Drug: Vinorelbine
Drug: Carboplatin

First Posted Date: 2007-07-11

Last Posted Date: 2014-07-09

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 275

Registration Number: NCT00499109

Locations: 🇺🇸
Leesburg Regional Medical Center, Leesburg, Florida, United States
🇺🇸
Center for Cancer Care & Research/Watson, Lakeland, Florida, United States
🇺🇸
Johns Hopkins Sidney Kimmell Comprehensive Cancer Center, Baltimore, Maryland, United States

and more 6 locations